Last October, we had the privilege of participating in AquaNor 2023 in Trondheim, Norway. During our presence, we received numerous national and international visitors and clients linked to aquaculture, including Chilean producers, who extended us the invitation to join this traditional and relevant event. Since its beginnings, salmon farming has been one of the most outstanding economic sectors in the south of Chile, generating an industrial development that involves both large companies and local enterprises. AquaSur is presented as a unique opportunity to bring together these key players, facilitating the exchange of ideas with suppliers, and the exploration of new developments and technologies to strengthen an increasingly dynamic and sustainable industry. It also gives producers the opportunity to express their concerns and needs, fostering collaboration for the common good. While salmon farming faces many challenges, our main objective is to promote sustained and sustainable growth. By participating, we aim to detect and analyze the main challenges of the sector, working on health solutions with preventive measures in the short, medium and long term. We aim to contribute to the development of a more sustainable industry, and to reaffirm its crucial role in global food. va is part of the EW Group, specialized in genetics, nutrition and animal health. With a presence in more than 100 countries and a constant international growth, we are a company committed to the prevention of diseases in food-producing animals, through the development and delivery of high-quality, long-term solutions. Our offer includes autogenous bacterial and viral vaccines for intensive animal production. With these vaccines, we are committed to providing appropriate preventive solutions for maximum performance, efficient use of resources and support the reduction of antibiotic use. We recognize the importance of sustainable animal protein production, which is why our R&D teams collaborate closely to develop innovative line vaccines and autogenous vaccines. In addition, we are working on new vaccine technologies to further advance the sustainability of the industry. We invite everyone to participate and be part of this important meeting.